Anan Copty ’94: A Palestinian Christian Physicist’s Quest to Cure Cancer and Build Peace
Posted on September 26, 2024 by College Communications in Alumni Stories, Featured.
Anan Copty ’94 (physics), Gordon College’s Alumni of the Year for 2024, is a Palestinian Christian with an Israeli passport. He’s worked in fields like astrophysics and semiconductor development and production, from the Harvard Physics Department and the Harvard-Smithsonian Astrophysics Center, Harvard Medical School, to Intel and RF MEMS. He helped build the space-instrument satellite SOHO, which is still in orbit measuring parts of the sun, and MRI machines for Brigham and Women's Hospital.
Perhaps his greatest achievement yet is starting his own company, SynergyMed, which develops noninvasive cancer treatments while employing people of all faiths and backgrounds. “When I first started SynergyMed, one of my missions was to treat cancer, but also to have an integration of people—Palestinians, Israelis, and more—to demonstrate that we can work together in a peaceful way despite the conflict,” he says.
A New Cancer Treatment
After a long career in Boston, Copty returned to Jerusalem to earn a Ph.D. in physics and then took a job at Intel. But as the years passed, he noticed many of his friends were passing away from breast cancer. This prompted Copty to start researching cancer treatments. Every available option had terrible side effects; chemo and radiation therapy would destroy tumors but also healthy tissue and immune systems. Surgery also significantly impacts the quality of life for patients.
Copty wanted to use his background in medical physics to figure out how to nonsurgically shrink a tumor without hurting the patient. He founded SynergyMed in 2019, hiring engineers, physicists and doctors from a variety of ethnic and religious backgrounds to develop medical devices that could treat cancer without side effects. The device they created uses thermal ablation technology to kill tumors in mice in only a few days, and in 10 days with larger animals.
Copty is optimistic that SynergyMed’s device will be effective in its current human trials stage. If it is, and the FDA approves it, the device could be revolutionary for cancer treatment of solid superficial tumors in humans and the veterinary market. And once the company has raised enough capital, SynergyMed aims to take its technology to every country in the world and help everyone who has need of it, regardless of who they are. “I feel like all people deserve to have a better quality of life,” Copty says.
Working Towards Conflict Resolution
SynergyMed has a dual mission. Besides providing better alternatives for cancer treatment, Copty also hopes his company will be an example to the world of bringing hope and reconciliation to the Middle East conflict and other war-stricken areas by hiring workers from different religious and ethnic backgrounds—including Christians, Muslims and Jews—in an employment model that is rare for the region.
“In Palestine there are really not that many innovative companies right now,” he says. “The political situation takes up so many resources, so a lot of the talented people in science, business and engineering actually end up leaving the country, or they are working in a bakery or in a gas station. So, when they work with me at SynergyMed, they feel like they're doing something great; it has a good impact.”
As SynergyMed grows Copty hopes one day, when things are more stable, to form a partnership with Gordon College to bring student interns to Jerusalem to work at his company there, and then send employees from the Middle East to work at a base for SynergyMed near Gordon.
"I want to reach as many patients as possible, all over the world,” Copty says. “We want to have a diverse group of people who work together and learn about the goodness of each other and practice kindness—to see more humanized versions of each other.”
Listening, Learning and Loving
Through every twist and turn of Copty’s eclectic career, the theme of his journey has been loving and learning from people vastly different from him because he was willing to listen to them.
“A lot of the education I got at Gordon was from hanging out with other students and having midnight discussions about things like women being priests or ministers, how the church can show love to gay people, gun control issues, war and peace...a lot of those discussions happened in a nice, friendly way,” he says.
When he worked in Boston alongside non-Christians, physics provided an opportunity for Copty to have conversations about faith with some of the smartest people in the world. “Most scientists unfortunately think that if you are a real scientist, you should be anti-religion, because they think there's no proof for religion,” he says. “But then when we had actual discussions, and they heard my point of view, they said, ‘Well, maybe we don't believe in what you believe. But at least you are showing it in a different way to us.’"
SynergyMed wasn’t Copty’s first entrepreneurial venture, either. His first attempt at starting a company to treat cancer failed. But then he went back and listened to real cancer patients and survivors to see what they needed from treatment, not what he thought they needed. He had to be willing to humble himself and learn more about running a business to make his second attempt succeed. More discussions like these are what will help our broken world heal—and it has to start from a place of love.
“I think Gordon is a great place to help think and go through these questions and discussions, and I think it helped me a lot,” he says. “So, my message is to try to be Christ-like. Christ was about love and loving everybody, no matter what they are, no matter their political beliefs or religion.”
Share
- Share on Facebook
- Share on X (Formerly Twitter)
- Share on LinkedIn
- Share on Email
-
Copy Link
-
Share Link
Categories
Categories
Archives
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014